You just read:

Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations

News provided by

Mitsubishi Tanabe Pharma America, Inc.

Aug 28, 2019, 10:00 ET